The global oral solid dosage (OSD) contract manufacturing market was valued at USD 10.2 billion in 2025 and is projected to increase from USD 11.1 billion in 2026 to USD 21.3 billion by 2033, registering a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033. North America accounted for the largest regional revenue share at 38.7% in 2025, while Asia Pacific is expected to experience the fastest growth over the forecast period.

Market expansion is primarily driven by increasing pharmaceutical outsourcing, rising demand for generic medicines following patent expirations, advancements in drug delivery technologies, and growing emphasis on pharmaceutical supply chain resilience. Contract development and manufacturing organizations (CDMOs) are becoming strategic partners for pharmaceutical and biotechnology companies seeking cost-efficient production, specialized manufacturing capabilities, regulatory expertise, and faster commercialization.

Key Market Trends and Insights

• By product: Tablets held the largest market share, accounting for 32.4% in 2025.
• By mechanism: The immediate-release segment is expected to register significant growth from 2026 to 2033.
• By end use: Large pharmaceutical companies accounted for the largest market share in 2025.
• Regional leadership: North America dominated the global market with a 38.7% revenue share in 2025.
• Regional growth: Asia Pacific is projected to record the fastest CAGR during the forecast period.
• Country-level performance: The U.S. held the largest country-level market share in 2025.

Go Deeper! Ask Prism AI

about the Global oral solid dosage contract manufacturing market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Key Growth Drivers of the Oral Solid Dosage Contract Manufacturing Market

1. Increasing Pharmaceutical Outsourcing to CDMOs

Pharmaceutical and biotechnology companies are increasingly outsourcing oral solid dosage manufacturing to CDMOs to reduce capital expenditure, streamline operations, and improve production efficiency. Establishing in-house capabilities for formulation development, scale-up, and commercial manufacturing requires substantial investments in facilities, specialized equipment, skilled personnel, and regulatory compliance.

Partnering with CDMOs enables pharmaceutical companies to concentrate on research and development, clinical trials, and commercialization while accessing established manufacturing infrastructure and technical expertise. Outsourcing also provides flexible production capacity, specialized formulation technologies, and support for regulatory requirements across different markets.

This trend is particularly significant among small and mid-sized biotechnology companies that lack dedicated manufacturing facilities. Large pharmaceutical companies are also leveraging outsourcing to optimize operating costs, improve resource allocation, and accelerate time-to-market.

For example, in December 2025, Bora Pharmaceuticals and Corealis Pharma partnered to provide integrated oral solid dosage development and manufacturing services. The collaboration combines early-stage development expertise with commercial-scale manufacturing capabilities, illustrating the industry's focus on integrated outsourcing solutions.

Download a free sample report or claim your copy of this full market intelligence report

3. Advancements in Drug Delivery Technologies and Specialized Formulations

Continuous advancements in pharmaceutical formulation and drug delivery technologies are increasing the technical requirements of oral solid dosage manufacturing. Pharmaceutical companies are developing more specialized products, including highly potent oral solid dosage (HPOSD) drugs, which require advanced containment systems, dedicated manufacturing infrastructure, and stringent occupational safety protocols.

These requirements can make in-house manufacturing complex and capital-intensive. Consequently, pharmaceutical companies are increasingly relying on CDMOs with specialized facilities, established quality management systems, and experience handling complex formulations.

Evolving regulatory expectations and occupational safety requirements are further reinforcing the need for qualified manufacturing partners. CDMOs can help companies manage technology transfer, improve production scalability, and implement robust manufacturing processes designed to minimize deviations and improve first-pass quality.

Demand for specialized manufacturing capabilities is therefore expected to create opportunities for CDMOs investing in advanced containment technologies, formulation expertise, and integrated development-to-commercialization services.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Regional Insights

North America: Largest Regional Market

North America dominated the oral solid dosage contract manufacturing market in 2025, accounting for 38.7% of global revenue. The region's position reflects the importance of its pharmaceutical industry and the demand for outsourced manufacturing, specialized formulation capabilities, and established regulatory and quality systems.

The U.S. held the largest country-level market share in 2025. Demand for contract manufacturing services is supported by pharmaceutical product development, generic drug commercialization, and the need for flexible production capacity.

Asia Pacific: Fastest-Growing Regional Market

Asia Pacific is projected to register the fastest CAGR from 2026 to 2033. Growth opportunities are associated with expanding pharmaceutical manufacturing capacity, increasing demand for generic medicines, and the growing role of regional manufacturers in global pharmaceutical supply chains.

The region's manufacturing capabilities and potential to support cost-efficient production are also relevant to pharmaceutical companies seeking to diversify sourcing and establish geographically distributed manufacturing networks.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Competitive Landscape: Key Oral Solid Dosage Contract Manufacturing Companies

The global oral solid dosage contract manufacturing market includes established pharmaceutical manufacturers and CDMOs offering formulation development, technology transfer, and commercial production services.

Key companies profiled in the market include:

• Catalent, Inc.
• Lonza
• Aenova Group
• Boehringer Ingelheim International GmbH
• Jubilant Pharmova Limited
• Patheon Pharma Services
• Recipharm AB
• Corden Pharma International
• Siegfried Holding AG

Explore our dedicated business services:

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today